Centessa Pharmaceuticals (CNTA) Corporate presentation summary

Mission and financial position

• Focused on discovering and developing transformational orexin-focused medicines targeting sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

• Aims to build a best-in-class/first-in-class orexin receptor 2 (OX2R) agonist franchise with robust clinical milestones expected in 2026.

• Maintains a strong balance sheet with an estimated cash runway into mid-2028, supported by $619 million in pro forma cash, cash equivalents, and investments.

Pipeline and clinical development

• ORX750 is advancing for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), with Phase 2a data showing potential best-in-class efficacy and favorable safety.

• ORX142 is in Phase 1 with healthy volunteers, showing high potency, differentiated pharmacokinetics, and favorable tolerability; patient studies planned for Q1 2026.

• ORX489 is progressing through IND-enabling studies, with clinical studies planned for Q1 2026, targeting neuropsychiatric disorders.

• Earlier-stage OX2R agonists are in development for additional indications.

Clinical data and efficacy highlights

• ORX750 demonstrated statistically significant, clinically meaningful, and dose-dependent improvements in sleep latency and cataplexy rates in NT1, NT2, and IH.

• Safety profile for ORX750 is generally favorable, with most adverse events being mild to moderate and transient; most common were pollakiuria, insomnia, dizziness, and headache.

• ORX142 showed rapid onset, high selectivity, and significant improvements in sleep latency in healthy volunteers.